Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 8/20 | 0.64 |
| ▸ | PYGM | P11217 | 3/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946369 | 1.00 | TK2 (0.64) | TK2PYGMP2RY2 | |
| SCHEMBL20456372 | 1.00 | TK2 (0.64) | TK2PYGMP2RY2 | |
| SCHEMBL768243 | 0.93 | TK2 (0.54) | TK2PYGM | |
| SCHEMBL16943168 | 0.93 | TK2 (0.54) | TK2PYGM | |
| SCHEMBL14946356 | 0.86 | P2RY6 (0.49) | TK2P2RY2 | |
| SCHEMBL18561550 | 0.86 | P2RY6 (0.49) | TK2P2RY2 | |
| SCHEMBL20456178 | 0.84 | TK2 (0.58) | TK2PYGMP2RY2 | |
| SCHEMBL13412991 | 0.83 | TK1 (0.65) | TK2 | |
| SCHEMBL5057505 | 0.83 | TK1 (0.65) | TK2 | |
| SCHEMBL5057499 | 0.83 | TK1 (0.65) | TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | TK2 151/4885PYGM 1594/4885P2RY2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.